Cargando…
Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment
INTRODUCTION: There is no effective treatment plan for coronavirus disease 2019 (COVID-19). We employed a combination of Chinese and Western medicine treatment for some COVID-19 inpatients. METHODS: This study was a prospective cohort study that observed non-critical COVID-19 inpatients. The differe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675424/ https://www.ncbi.nlm.nih.gov/pubmed/36411815 http://dx.doi.org/10.2147/IJGM.S391024 |
_version_ | 1784833369208520704 |
---|---|
author | Yi, Yongxin Fang, Jiayang Liu, Yunzhu Gao, Yidong Lin, Weizhi Hao, Dongdong Zhang, Xing Zhang, Min |
author_facet | Yi, Yongxin Fang, Jiayang Liu, Yunzhu Gao, Yidong Lin, Weizhi Hao, Dongdong Zhang, Xing Zhang, Min |
author_sort | Yi, Yongxin |
collection | PubMed |
description | INTRODUCTION: There is no effective treatment plan for coronavirus disease 2019 (COVID-19). We employed a combination of Chinese and Western medicine treatment for some COVID-19 inpatients. METHODS: This study was a prospective cohort study that observed non-critical COVID-19 inpatients. The differences will be observed in the time from admission to two consecutive 2019-nCoV nucleic acid test negatives and the Visual Analog Scale (VAS) score between the two groups. RESULTS: A total of 254 confirmed COVID-19 patients were included in this study. The median time from the admission to two consecutive negative nucleic acid tests was 14 days for the integrated Chinese and Western Medicine (ICWM) group, while the Western Medicine (WM) group was 16 days. Besides, the median VAS score of the ICWM group was 0, which was an average decrease of 2 points compared to the time of admission. CONCLUSION: For non-critical COVID-19 patients, it was safe and have more benefits to add traditional Chinese medicine decoction based on WM treatment. |
format | Online Article Text |
id | pubmed-9675424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-96754242022-11-20 Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment Yi, Yongxin Fang, Jiayang Liu, Yunzhu Gao, Yidong Lin, Weizhi Hao, Dongdong Zhang, Xing Zhang, Min Int J Gen Med Original Research INTRODUCTION: There is no effective treatment plan for coronavirus disease 2019 (COVID-19). We employed a combination of Chinese and Western medicine treatment for some COVID-19 inpatients. METHODS: This study was a prospective cohort study that observed non-critical COVID-19 inpatients. The differences will be observed in the time from admission to two consecutive 2019-nCoV nucleic acid test negatives and the Visual Analog Scale (VAS) score between the two groups. RESULTS: A total of 254 confirmed COVID-19 patients were included in this study. The median time from the admission to two consecutive negative nucleic acid tests was 14 days for the integrated Chinese and Western Medicine (ICWM) group, while the Western Medicine (WM) group was 16 days. Besides, the median VAS score of the ICWM group was 0, which was an average decrease of 2 points compared to the time of admission. CONCLUSION: For non-critical COVID-19 patients, it was safe and have more benefits to add traditional Chinese medicine decoction based on WM treatment. Dove 2022-11-15 /pmc/articles/PMC9675424/ /pubmed/36411815 http://dx.doi.org/10.2147/IJGM.S391024 Text en © 2022 Yi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yi, Yongxin Fang, Jiayang Liu, Yunzhu Gao, Yidong Lin, Weizhi Hao, Dongdong Zhang, Xing Zhang, Min Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment |
title | Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment |
title_full | Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment |
title_fullStr | Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment |
title_full_unstemmed | Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment |
title_short | Clinical Characteristics of 254 COVID-19 Inpatients in Yichang, Hubei, China, and Efficacy of Integrated Chinese and Western Medicine Treatment |
title_sort | clinical characteristics of 254 covid-19 inpatients in yichang, hubei, china, and efficacy of integrated chinese and western medicine treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675424/ https://www.ncbi.nlm.nih.gov/pubmed/36411815 http://dx.doi.org/10.2147/IJGM.S391024 |
work_keys_str_mv | AT yiyongxin clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment AT fangjiayang clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment AT liuyunzhu clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment AT gaoyidong clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment AT linweizhi clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment AT haodongdong clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment AT zhangxing clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment AT zhangmin clinicalcharacteristicsof254covid19inpatientsinyichanghubeichinaandefficacyofintegratedchineseandwesternmedicinetreatment |